NASDAQ:APEN Apollo Endosurgery (APEN) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free APEN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$9.87▼$10.0052-Week Range N/AVolume1.66 million shsAverage Volume1.43 million shsMarket Capitalization$579.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Apollo Endosurgery alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Apollo Endosurgery Stock (NASDAQ:APEN)Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.Read More Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide APEN Stock News HeadlinesFebruary 1, 2024 | morningstar.comApollo Pipes Ltd 531761November 12, 2023 | nypost.comAstronaut Frank Borman, commander of the first Apollo mission to the moon, dead at 95April 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.November 5, 2023 | cnn.comApollo astronaut Ken Mattingly, who helped save the crew of Apollo 13, has diedMay 10, 2023 | marketwatch.comGastric Band and Gastric Balloon Market to Witness Growth Acceleration | Apollo Endosurgery, Cousin Surgery, Spatz FGIA IncApril 1, 2023 | finance.yahoo.comApollo Endosurgery Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 29, 2023 | seekingalpha.comAPEN Apollo Endosurgery, Inc.March 7, 2023 | finance.yahoo.comDoes This Valuation Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Imply Investors Are Overpaying?April 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 2, 2023 | benzinga.comSHAREHOLDER ALERT: Morris Kandinov Investigating ALBO, APEN, ATCX and PAYA Mergers and Acquisitions; Shareholders are Encouraged to Contact the FirmJanuary 11, 2023 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Apollo Endosurgery, Inc. (APEN)December 15, 2022 | apnews.comSTOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SAL, VVNT, APEN, GRAYDecember 13, 2022 | finance.yahoo.comApollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with ObesityDecember 8, 2022 | msn.com$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 TodayDecember 5, 2022 | wsj.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Apollo Endosurgery, Inc. - APENNovember 30, 2022 | bizjournals.comBoston Scientific shells out $615M for gastro device firmNovember 29, 2022 | nasdaq.comBoston Scientific to buy Apollo Endosurgery for $417 millionNovember 29, 2022 | reuters.comBoston Scientific to acquire Apollo Endosurgery in $615 mln dealNovember 29, 2022 | finance.yahoo.comApollo Endosurgery to be Acquired by Boston ScientificNovember 29, 2022 | finance.yahoo.comBoston Scientific to acquire Apollo Endosurgery for $615 million in cashNovember 21, 2022 | finance.yahoo.comApollo Endosurgery Completes Transition to European MDR Requirements for the OverStitch Systems, BIB and Orbera 365 intragastric balloons, and OverTube.November 8, 2022 | finance.yahoo.comApollo Endosurgery, Inc. (NASDAQ:APEN) is largely controlled by institutional shareholders who own 58% of the companyNovember 7, 2022 | finance.yahoo.comApollo Endosurgery to Participate in Upcoming Investor ConferencesNovember 1, 2022 | finance.yahoo.comApollo Endosurgery, Inc. Reports Record $19.6 million Global Revenue in Third Quarter 2022October 18, 2022 | finance.yahoo.comApollo Endosurgery to Report Third Quarter Results on November 1, 2022October 12, 2022 | nasdaq.comInvestors in Apollo Endosurgery (NASDAQ:APEN) have made a favorable return of 92% over the past three yearsOctober 10, 2022 | msn.comShort Volatility Alert: Apollo Endosurgery, Inc.See More Headlines Receive APEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/31/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:APEN CUSIPN/A CIK1251769 Webwww.apolloendo.com Phone(512) 279-5100Fax858-678-0900Employees202Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,840,000.00 Net Margins-51.84% Pretax Margin-51.08% Return on Equity-89.48% Return on Assets-33.76% Debt Debt-to-Equity Ratio1.04 Current Ratio2.35 Quick Ratio1.89 Sales & Book Value Annual Sales$76.86 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / BookN/AMiscellaneous Outstanding Shares57,972,000Free Float47,943,000Market Cap$579.72 million OptionableNot Optionable Beta2.31 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesCharles S. McKhannPresident, Chief Executive Officer & DirectorJohn MolesphiniExecutive Vice President-OperationsJeffrey G. BlackChief Financial Officer, Secretary & TreasurerChristopher J. GostoutChief Medical OfficerTiffanie GilbrethVice President-Clinical & Medical AffairsKey CompetitorsEmbectaNASDAQ:EMBCSI-BONENASDAQ:SIBNIradimedNASDAQ:IRMDOrthofix MedicalNASDAQ:OFIXTreace Medical ConceptsNASDAQ:TMCIView All Competitors APEN Stock Analysis - Frequently Asked Questions How were Apollo Endosurgery's earnings last quarter? Apollo Endosurgery, Inc. (NASDAQ:APEN) announced its earnings results on Sunday, October, 31st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.05. The biotechnology company earned $16.35 million during the quarter, compared to analysts' expectations of $16.20 million. Apollo Endosurgery had a negative trailing twelve-month return on equity of 89.48% and a negative net margin of 51.84%. During the same quarter in the prior year, the business earned ($0.11) earnings per share. What other stocks do shareholders of Apollo Endosurgery own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES). This page (NASDAQ:APEN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Goldtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe AI stock to buy right nowStockEarningsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollo Endosurgery, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
